Celebrex®
Celecoxib
Version 2025-04 · Last reviewed April 1, 2025 · Methodology
List Price
$310
With Insurance
$15–40 (generic)
The Short Version
Plain-language summary
Celebrex (Celecoxib) targets only the inflammation-causing enzyme (COX-2) while sparing the one that protects your stomach lining (COX-1). This means less stomach irritation than regular anti-inflammatory drugs like ibuprofen.
How it works: Celecoxib selectively inhibits the COX-2 enzyme, an inducible enzyme upregulated at sites of inflammation, injury, and fever. It largely spares COX-1, the constitutive enzyme that protects the stomach lining and enables platelet clotting. The COX-2 "selectivity" was the entire marketing premise after Vioxx, the idea being that you could block inflammation without causing stomach ulcers. The heart and blood vessel catch emerged immediately: COX-2 produces prostacyclin (PGI2), a potent vasodilator and antiplatelet molecule in blood vessel walls. Block COX-2, and PGI2 drops. COX-1's thromboxane A2 (TXA2, pro-clotting, pro-vasoconstriction) is left unopposed. The result is a prothrombotic imbalance that tilts the vascular environment toward clot formation, the same mechanism that caused Vioxx to kill an estimated 38,000 Americans. Celecoxib has more balanced COX-1/2 selectivity than rofecoxib (Vioxx), which is why it survived the class-wide reckoning of 2004, but the mechanism and the black box warning are the same.
What people most commonly report
Usually mild and resolves within the first 2 weeks; ensure adequate hydration
Check the evidence section for details on who funded the research.
What Else the Evidence Supports
Non-drug options with clinical backing
The COX-2 "selectivity" was always a GI marketing story, Vioxx and the CLASS trial proved the cardiovascular and long-term GI risks remain. Curcumin matched ibuprofen for knee OA pain in a head-to-head RCT with no cardiovascular, renal, or thrombotic risk.
RCT: equal efficacy to ibuprofen 800mg for knee osteoarthritis pain at 6 weeks; no GI, cardiovascular, or thrombotic effects; anti-inflammatory through NF-κB suppression rather than COX inhibition.
Anti-inflammatory through resolvin/protectin synthesis; multiple RCTs show 30–60% reduction in NSAID requirements in RA and chronic pain; no cardiovascular or thrombotic risk, actually protective.
RCT: significant OA pain reduction at 8 weeks; no GI damage or cardiovascular effects; complementary mechanism to COX inhibition.
Multiple RCTs: Mediterranean diet reduces CRP, IL-6, and joint inflammation scores.
What This Really Costs
Long-term cost projection based on current pricing
Monthly
$40
$28 w/ insurance
without insurance
Annual
$480
$336 w/ insurance
without insurance
10 Years
$4.8K
$3.4K w/ insurance
without insurance
30 Years
$14.4K
$10.1K w/ insurance
without insurance
Lifestyle alternative: $0/month in prescriptions. Curcumin (BCM-95 or C3 complex, 500mg twice daily) - RCT: equal efficacy to ibuprofen 800mg for knee osteoarthritis pain at 6 weeks; no GI, cardiovascular, or thrombotic effects; anti-inflammatory through NF-κB suppression rather than COX inhibition.
The average American retiree spends $165,000 on healthcare after retirement (Fidelity, 2024). Informed choices today compound over decades.
Related Evidence
Explore related medications reviewed on EvidentMeds
FDA Black Box Warning
CARDIOVASCULAR THROMBOTIC EVENTS & SERIOUS GI RISK
COX-2 selective and non-selective NSAIDs carry the same class-wide black box for MI and stroke risk, risk increases with dose and duration. Same black box for GI ulcers, bleeding, and perforation. Not for use in perioperative pain from CABG surgery.
Strict Contraindications
Metabolic & Lifestyle Alternatives
Pain & Inflammation Without Cardiovascular or GI Compromise
The COX-2 "selectivity" was always a GI marketing story, Vioxx and the CLASS trial proved the cardiovascular and long-term GI risks remain. Curcumin matched ibuprofen for knee OA pain in a head-to-head RCT with no cardiovascular, renal, or thrombotic risk.
Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.
Curcumin (BCM-95 or C3 complex, 500mg twice daily)
Most bioavailable curcuminoid, pairs with piperine or phospholipid complex
RCT: equal efficacy to ibuprofen 800mg for knee osteoarthritis pain at 6 weeks; no GI, cardiovascular, or thrombotic effects; anti-inflammatory through NF-κB suppression rather than COX inhibition
Omega-3 EPA (2–4g/day)
Fish oil or algae-based EPA, resolvin synthesis pathway
Anti-inflammatory through resolvin/protectin synthesis; multiple RCTs show 30–60% reduction in NSAID requirements in RA and chronic pain; no cardiovascular or thrombotic risk, actually protective
Boswellia serrata (AKBA, 100–250mg/day)
Frankincense extract, inhibits 5-LOX pathway (not COX)
RCT: significant OA pain reduction at 8 weeks; no GI damage or cardiovascular effects; complementary mechanism to COX inhibition
Low-inflammatory diet (Mediterranean or animal-based with omega-3)
Reduce seed oils (omega-6), processed carbohydrates, refined sugars, all of which upregulate COX-2 endogenously
Multiple RCTs: Mediterranean diet reduces CRP, IL-6, and joint inflammation scores. Reducing linoleic acid (seed oils) reduces the substrate for COX-2 inflammatory metabolite production.
Physical therapy + weight management (OA)
Every 1 lb of body weight removed = 4 lbs reduction in knee joint force loading
AHRQ evidence review: exercise therapy equivalent to NSAIDs for OA symptom control at 12 weeks; no CV, GI, or renal risk; durable results vs. drug-dependent effects
Key Studies
Global Prescribing & Pricing
COX-2 inhibitors are prescribed more cautiously in Europe post-Vioxx; the UK NICE explicitly restricts celecoxib to patients at high GI risk who cannot tolerate non-selective NSAIDs
United States
$20–60 (generic)/mo
Heavily prescribed; still marketed by Pfizer with the GI advantage narrative despite the black box
No prerequisite GI risk assessment required before prescribing; DTC advertising allowed
Often covered; prior auth sometimes required for brand
United Kingdom
~$12–25/mo
NICE CG177: only recommended in patients with documented high GI risk who have failed standard NSAIDs; lowest effective dose for shortest time
GP must document GI risk reason for COX-2 selection; NICE explicitly states COX-2 selectivity does not eliminate cardiovascular risk
Covered by NHS with documented indication
Germany
~$15–30/mo
G-BA (benefit assessment agency) rates celecoxib as "no added benefit" over non-selective NSAIDs in most patients given equivalent cardiovascular risk
Statutory insurers may restrict reimbursement without documented GI risk indication; cardiovascular risk assessment mandatory
Covered with documented GI indication
France
~$10–25/mo
HAS (French drug agency) restricted COX-2 inhibitor reimbursement post-Vioxx; similar restriction to UK, high GI risk plus contraindication to non-selective NSAID
Pharmacist required to document GI risk history; lower prescribing rate than US
Covered only with specific documented GI risk
Australia
~$15–30/mo
TGA-approved; PBS subsidy restricted to patients with high GI risk, requires documented history of GI ulcer or bleeding
PBS authority required; cardiovascular risk assessment strongly encouraged before initiation; no DTC advertising allowed
PBS covered with authority script
After Vioxx killed an estimated 38,000 Americans, regulatory agencies worldwide tightened COX-2 inhibitor prescribing. The UK, Germany, France, and Australia now restrict reimbursement to patients with documented high GI risk, acknowledging that COX-2 selectivity does not reduce cardiovascular risk and that the GI advantage disappears in patients on aspirin. The US remains the outlier, permitting DTC advertising and unrestricted prescribing.
Clinical Trials & Funding
Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid - they undergo the same FDA review - but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.
Key Efficacy Results
CLASS: GI advantage shown at 6 months, disappeared at 12 months (12-month data suppressed). PRECISION: Non-inferior to ibuprofen and naproxen for CV safety, but 90% of patients were on aspirin, which masks COX-2 selective cardiovascular risk.
Referenced Studies
Each study shows its evidence level and Cochrane RoB-2 risk-of-bias rating - tap the bias badge for details.
Evidence & Transparency
Cochrane RoB-2 (Risk of Bias)
Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗
CMS Open Payments
Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears", never definitive clinical claims. CMS Open Payments ↗
Live Clinical Trials
Live from ClinicalTrials.gov · refreshed every 4 hours
Currently enrolling, active, and recently completed studies involving Celecoxib. Data is pulled directly from the U.S. National Library of Medicine.
Recent Research
Live from PubMed · peer-reviewed literature · refreshed every 4 hours
Most recently indexed clinical trials and systematic reviews mentioning Celecoxib in PubMed.
Source Documentation
Structured citations for referenced clinical trials
Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.
| Trial | Registry ID | Cite |
|---|---|---|
| CLASS Trial, JAMA 2000 (6-month only) | PMID:10983798 | |
| Juni et al., Full 12-Month CLASS Data (Lancet 2002) | PMID:12427958 | |
| PRECISION Trial (NEJM 2016) | PMID:27356222 |
Bias ratings use Cochrane RoB-2 methodology. Editorial assessment - not a certified Cochrane review.
Our MethodologyCommon Side Effects
While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.
Hypertension / elevated blood pressure
13%Monitor BP within 2–4 weeks of starting; NSAIDs cause sodium retention. This effect persists even with COX-2 selectivity.
Headache
15%Usually mild and resolves within the first 2 weeks; ensure adequate hydration
Diarrhea
11%Generally mild; reduces with food co-administration
Abdominal pain / dyspepsia
8%Take with food; celecoxib causes significantly less GI damage than non-selective NSAIDs, but it is not risk-free, especially at higher doses or with alcohol
Peripheral edema / fluid retention
4–5%Report ankle swelling; especially relevant in patients with heart failure or on diuretics
Dizziness
5%Avoid driving until effect is known; increases fall risk in elderly
Rhinitis / upper respiratory symptoms
5%Usually mild and non-allergic; monitor for signs of hypersensitivity (hives, bronchospasm) especially in aspirin-sensitive asthma
Serious Adverse Effects
- • Myocardial infarction (MI) and stroke, black box; same class-wide risk as all NSAIDs including Vioxx; risk increases with dose and duration
- • GI ulcers and bleeding, less than non-selective NSAIDs at 6 months, but CLASS trial showed advantage disappears at 12 months
- • Acute kidney injury, NSAIDs reduce prostaglandin-mediated renal perfusion; dangerous in dehydration, elderly, or with ACE inhibitors/diuretics
- • Hepatotoxicity, rare but reported; monitor liver enzymes in long-term use
- • Severe skin reactions (SJS/TEN), rare; stop immediately at first sign of rash
- • Exacerbation of heart failure, sodium retention worsens fluid overload
- • Aspirin-sensitive asthma, COX-2 inhibitors can still trigger bronchoconstriction in aspirin-sensitive patients
Drug Interactions
Major Interactions (Avoid)
Moderate Interactions (Caution)
Food Interactions
When to Contact Your Doctor
This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician - do not wait for your next scheduled appointment.
Contact soon if you notice
- Myocardial infarction (MI) and stroke, black box; same class-wide risk as all NSAIDs including Vioxx; risk increases with dose and duration
- GI ulcers and bleeding, less than non-selective NSAIDs at 6 months, but CLASS trial showed advantage disappears at 12 months
- Acute kidney injury, NSAIDs reduce prostaglandin-mediated renal perfusion; dangerous in dehydration, elderly, or with ACE inhibitors/diuretics
- Hepatotoxicity, rare but reported; monitor liver enzymes in long-term use
- Black, tarry, or bloody stools, GI bleeding; stop immediately and seek emergency care
Also discuss if you want to
- Review whether this medication is still appropriate for you
- Consider dosage adjustments based on response
- Explore lifestyle or non-drug alternatives
- Understand stopping or tapering options
- Plan monitoring labs and follow-up
In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.
Special Populations
Safety classifications for specific groups - discuss with your provider before use.
From 20 weeks onward: causes fetal kidney dysfunction and oligohydramnios (low amniotic fluid), FDA warning 2020. First trimester: potential miscarriage risk. Celecoxib is a sulfonamide, additional allergy concern. Use acetaminophen for pain during pregnancy.
Limited data on transfer to breast milk. Occasional use likely low risk; avoid long-term or high-dose use. Ibuprofen (better-studied) is generally preferred for nursing mothers who need an NSAID.
Estrogen provided cardiovascular protection. After menopause that protection is lost, adding a COX-2 inhibitor on top of this increased baseline cardiovascular risk compounds the concern. The same black box warning applies regardless of age, but post-menopausal women are in the highest-risk demographic for NSAID-related cardiovascular events.
FDA-approved for juvenile idiopathic arthritis (JIA) in children ≥2 years. Not approved for general pain or fever in children, ibuprofen is the evidence-based OTC option. Celecoxib is not appropriate as a substitute for ibuprofen in children.
All NSAIDs, including COX-2 selective agents, are on the AGS Beers Criteria as high-risk in older adults. Celebrex does not escape this classification. Increased risk of GI bleeding, MI, heart failure exacerbation, and acute kidney injury. Use lowest dose for shortest time, with a PPI if unavoidable.
Celecoxib is not recommended in severe renal impairment (eGFR <30). All NSAIDs reduce prostaglandin-dependent renal perfusion, causing acute kidney injury in patients with reduced renal reserve, dehydration, or volume depletion.
Reduce dose by 50% in moderate hepatic impairment (Child-Pugh Class B). Avoid in severe hepatic impairment. Celecoxib is hepatically metabolized via CYP2C9, impaired metabolism increases exposure and toxicity risk.
FDA Adverse Event Reports
Patient-filed reports from the FDA FAERS database · refreshed daily
Community Reports
User-reported experiences - anonymous & anecdotal
Join the Conversation
Premium subscribers can share their experience and confirm others' reports.
Cancel anytime.
Stopping This Medication Safely
Celecoxib does not cause physical dependence and can be stopped at any time. Underlying inflammatory pain will return, address the root cause rather than taking an indefinite NSAID with cardiovascular risk.
What Published Research Shows About Stopping This Medication
This summarizes what published research documents, it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.
- ·Research shows no pharmacological taper is needed for celecoxib
- ·Research supports addressing the root cause of pain (weight management, physical therapy, omega-3, curcumin) rather than restarting
- ·For patients stopping due to GI or cardiovascular concern, research supports acetaminophen for pain and non-NSAID alternatives
- ·Research documents that abruptly switching from celecoxib to high-dose aspirin can cause significant GI bleeding due to combined platelet effects
Warning Symptoms, Contact Your Doctor If You Experience:
- Black, tarry, or bloody stools, GI bleeding; stop immediately and seek emergency care
- Chest pain, shortness of breath, sudden weakness, cardiovascular event; call 911
- Severe swelling, rapid weight gain, decreased urination, kidney failure
- Skin rash, blistering, or peeling, possible SJS/TEN; stop immediately
Never change or stop a medication without consulting your prescribing physician.
Questions for Your Doctor
$2.99, printable guide for your next appointment
Questions to Ask
- 1.I take low-dose aspirin for heart protection, is Celebrex still safer for my stomach in that case, or does the aspirin eliminate that advantage?
- 2.I have a history of MI or stroke, should I be taking any NSAID, or are there safer alternatives for my pain?
- 3.I'm on warfarin, how do I monitor for the interaction between celecoxib and my blood thinner?
- 4.Is my kidney function adequate for NSAID use, and how do we monitor it?
- 5.Has a trial of curcumin, omega-3, or physical therapy been tried first for my condition?
Lab Tests to Request
- Blood pressure (baseline and 2–4 weeks after starting)
- Kidney function (eGFR + creatinine)
- INR if on warfarin, within 1 week of starting
- Hemoglobin / CBC if used chronically (GI blood loss)
- Liver enzymes (ALT/AST), baseline and periodically in long-term use
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Get notified when we update Celebrex®
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.
Found this useful?
Help keep EvidentMeds editorially independent and community supported. Every dollar funds transparent medication data.